Vagus nerve stimulation for the treatment of fibromyalgia
First Claim
Patent Images
1. A method of reducing the severity of symptoms in patients suffering from fibromyalgia syndrome (FMS) comprising:
- a) determining a baseline level of pain in a patient;
b) surgically implanting electrodes in the patient connected directly to a patient'"'"'s vagus nerve so that the patient'"'"'s vagus nerve can be selectively and directly stimulated;
c) applying a therapeutic stimulation signal from a stimulus generator to the electrodes and stimulating the vagus nerve, wherein said therapeutic stimulation signal is up to 2 mA and is applied continuously for at least 12 weeks; and
d) determining a level of pain in the patient following application of therapeutic stimulation in step c), wherein a decrease in the level of pain following application of therapeutic stimulation in step c) as compared with the baseline level of pain is indicative of a reduction in the severity of FMS symptoms.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to the use of vagus nerve stimulation for the treatment of fibromyalgia which comprises applying a therapeutic stimulation signal from a stimulus generator, when activated, to at least some of plural electrodes implanted in stimulating relation of the patient'"'"'s vagus nerve and activating the stimulus generator to generate the therapeutic stimulation signal to alleviate the pain under treatment.
10 Citations
3 Claims
-
1. A method of reducing the severity of symptoms in patients suffering from fibromyalgia syndrome (FMS) comprising:
-
a) determining a baseline level of pain in a patient; b) surgically implanting electrodes in the patient connected directly to a patient'"'"'s vagus nerve so that the patient'"'"'s vagus nerve can be selectively and directly stimulated; c) applying a therapeutic stimulation signal from a stimulus generator to the electrodes and stimulating the vagus nerve, wherein said therapeutic stimulation signal is up to 2 mA and is applied continuously for at least 12 weeks; and d) determining a level of pain in the patient following application of therapeutic stimulation in step c), wherein a decrease in the level of pain following application of therapeutic stimulation in step c) as compared with the baseline level of pain is indicative of a reduction in the severity of FMS symptoms. - View Dependent Claims (2, 3)
-
Specification